leadf
logo-loader
viewRevive Therapeutics

Revive Therapeutics preparing to submit paperwork for a Phase 3 FDA study of Bucillamine

Revive Therapeutics (CSE: RVV) Chairman and CEO Michael Frank and Founder of Psilocin Pharma Corp Derrick Welsh joined Steve Darling from Proactive to discuss some recent developments for the company. Frank discusses the recent development in the repurposed drug Bucillamine and its potential use for respiratory conditions.

Welsh also told Proactive about the work Revive Therapeutics subsidiary Psilocin Corp is doing in the field of extraction and purification technology for the compound Psilocybin.

Quick facts: Revive Therapeutics

Price: 0.275 CAD

CSE:RVV
Market: CSE
Market Cap: $45.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read